Malinauskiene V, Zuzo A, Liakina V, Kazenaite E, Stundiene I. Menstrual cycle abnormalities in women with inflammatory bowel disease and effects of biological therapy on gynecological pathology. World J Clin Cases 2023; 11(21): 4989-4995 [PMID: 37583859 DOI: 10.12998/wjcc.v11.i21.4989]
Corresponding Author of This Article
Valentina Liakina, PhD, Senior Researcher, Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 2 Santariskiu Str., Vilnius 01513, Lithuania. valentina.liakina@santa.lt
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jul 26, 2023; 11(21): 4989-4995 Published online Jul 26, 2023. doi: 10.12998/wjcc.v11.i21.4989
Menstrual cycle abnormalities in women with inflammatory bowel disease and effects of biological therapy on gynecological pathology
Vaidota Malinauskiene, Anastasija Zuzo, Valentina Liakina, Edita Kazenaite, Ieva Stundiene
Vaidota Malinauskiene, Valentina Liakina, Edita Kazenaite, Ieva Stundiene, Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius 01513, Lithuania
Anastasija Zuzo, Faculty of Medicine, Vilnius University, Vilnius 01513, Lithuania
Valentina Liakina, Department of Chemistry and Bioengineering, Faculty of Fundamental Sciences, Vilnius Tech, Vilnius 10223, Lithuania
Author contributions: Malinauskiene V and Zuzo A performed a literature search and wrote a manuscript draft; Kazenaite E, Liakina V, and Stundiene I revised the sources of the literature and the text of the manuscript; All authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Valentina Liakina, PhD, Senior Researcher, Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 2 Santariskiu Str., Vilnius 01513, Lithuania. valentina.liakina@santa.lt
Received: March 27, 2023 Peer-review started: March 27, 2023 First decision: May 31, 2023 Revised: June 14, 2023 Accepted: June 30, 2023 Article in press: June 30, 2023 Published online: July 26, 2023
Core Tip
Core Tip: In this review, our aim was to present possible menstrual disorders in patients with inflammatory bowel disease (IBD) and the effects of adalimumab and other anti-tumor necrosis factor (TNF) drugs on gynecological pathology. The correct diagnosis and selection of treatment for women with IBD and gynecological disorders can be a challenge for clinicians and can require a more careful and extensive examination of the patient. Furthermore, new studies show the possible widening use of biological therapies, such as reducing ovarian ischemia, preserving ovarian reserve, and reducing the degree of endometriosis. More detailed human studies are needed, as well as studies involving other anti-TNF-α drugs, to clarify their potential benefits in treating these conditions.
